anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
GOALS: We tested the hypothesis that water exchange (WE) achieved a significantly higher right colon flat polyp detection rate (rFPDR) than water immersion (WI).
BACKGROUND: Current endoscopy methods provide real-time morphology but not histopathology. Flat serrated polyps are difficult to find during colonoscopy. In 2022 2 studies reported that the serrated polyp detection rate (SPDR) significantly inversely predicted the development of interval cancers. In 2021 1 systemic review with meta-analysis showed that WE, but not WI increased SPDR. The relative contributions of WE and WI on rFPDR are unknown.
STUDY: Individual patient data from 3 reports comparing air insufflation, WI, and WE were pooled. Multiple logistic regression analysis was used to assess the factors associated with a higher rFPDR.
RESULTS: The pooled data showed that the rFPDR of air insufflation, WI, and WE were 15.4%, 14.1%, and 19.4% ( P =0.009), respectively. After adjusting for age and withdrawal time, multiple logistic regression analysis revealed that WE, when compared with WI, was significantly associated with a higher rFPDR (adjusted odds ratio[aOR]=1.53, P =0.002). Analysis of data on pathology and size were omitted to avoid duplicating our earlier publications.
CONCLUSIONS: Significantly higher rFPDR was achieved by WE. Water exchange rather than WI merits consideration for use to maximize rFPDR. Removal of flat polyps, and by inference serrated polyps, ensures their optimal management to minimize the occurrence of interval cancers. The potential benefit of WE in maximizing SPDR and minimizing interval cancers deserves evaluation in long-term randomized controlled studies focused on flat polyps detection.
A natural plant cleaning wet tissue and a preparation method thereof belong to the technical field of wet tissue research and development. The invention aims to solve the problems that an existing wet tissue is poor in cleaning effect and harmful to skin, and the wet tissue comprises liquid medicine and a wet tissue base material carrying the liquid medicine, wherein the liquid medicine comprises 4-8 parts of jojoba oil, 1-4 parts of grape seed oil and 2-6 parts of chamomile extract in parts by mass. The method comprises the following steps: mixing 3 raw materials for preparing medicinal liquid with 0.3 part of natural solubilizing component, adding pure water to 100 parts, stirring at normal temperature at 50rpm for 30 min; the liquid medicine is added into the wet tissue base material by adopting a repeated quantitative filling method. The natural solubilizing components are glyceryl oleate citrate and caprylic/capric triglyceride. The prepared wet tissue has the functions of effectively cleaning skin, improving skin moisturizing function, keeping skin moisture and reducing skin moisture loss. The preparation method is simple, can be used for industrial production, and adopts mild and safe raw materials.
The invention provides a process to produce highly active royal jelly ice cream, which comprises the improvement of production process of royal jelly materials. The invention adopts four measures to ensure the activity of the royal jelly in the ice cream. The first is to change production procedures of the royal jelly in existence. The activeness of the royal jelly taken in 48h after insects removal is 30 percent higher than that taken in 72h after the insects removal. The second is to substitute mechanical produced royal jelly for the manual produced royal jelly, which has received milk taking machine invention rights with horizontal high speed II type and III type invention declaration and improves 15 times of the working efficiency and activeness of royal jelly. The third is to strengthen supervisory measures and invent PNP-1 method and ensure royal jelly activeness contents in the highly active royal jelly ice cream. The fourth is to solve a contradiction that the ice cream materials need to be sterilized, but the royal jelly can not be treated under high temperature; therefore, when adopting 5 DEG C isotropic in the process of the highly active royal jelly ice cream, the royal jelly is added to keep the high activeness of the royal jelly in the ice cream.
Women in the High Intensity (intervention) arm are counseled by a wellness coach and have a group meeting each month. They are also interviewed four times (at baseline, 4 months, 8 months, and 12 months). Women in the high intensity group must have monthly contact with coaches during at least 9 of 12 months via participation in a group activity and/or monthly coaching to receive a "full dose" of the intervention.
In healthy pancreas, pancreatic stellate cells (PaSCs) synthesize the basement membrane, which is mainly composed of type IV collagen and laminin. In chronic pancreatitis (CP), PaSCs are responsible for the production of a rigid extracellular matrix (ECM) that is mainly composed of fibronectin and type I/III collagen. Reactive oxygen species evoke the formation of the rigid ECM by PaSCs. One source of reactive oxygen species is NADPH oxidase (Nox) enzymes. Nox1 up-regulates the expression of Twist1 and matrix metalloproteinase-9 (MMP-9) in PaSCs from mice with CP. This study determined the functional relationship between Twist1 and MMP-9, and other PaSC-produced proteins, and the extent to which Twist1 regulates digestion of ECM proteins in CP. Twist1 induced the expression of MMP-9 in mouse PaSCs. The action of Twist1 was not selective to MMP-9 because Twist1 induced the expression of types I and IV collagen, fibronectin, transforming growth factor, and α-smooth muscle actin. Luciferase assay indicated that Twist1 in human primary PaSCs increased the expression of MMP-9 at the transcriptional level in an NF-κB dependent manner. The digestion of type I/III collagen by MMP-9 secreted by PaSCs from mice with CP depended on Twist1. Thus, Twist1 in PaSCs from mice with CP induced rigid ECM production and MMP-9 transcription in an NF-κB-dependent mechanism that selectively displayed proteolytic activity toward type I/III collagen.
Participants receive romidepsin IV over 4 hours on days 1 and 8 or day 8 of cycle 1 and days 1 and 8 of subsequent cycles and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
This will be a prospective cohort study, in which a new sample of individuals attending cardiac rehabilitation programs will be assessed by clinical and physical variables and stratified in one of the three following risk classes: "low risk", "moderate risk", and "high risk" accordingly to the new risk stratification protocol. After that, the sample will be followed for 2 months of rehabilitation to the evaluation of the occurrence of signs and symptoms. The cardiac rehabilitation program from where the volunteers will be recruited is based on moderate-intensity aerobic exercise and resistance training. With these data, the reproducibility and efficiency of the protocol will be evaluated.
Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Only use Tretinoin Cream, USP (Emollient) to treat the condition that your doctor has prescribed it for. Do not give Tretinoin Cream, USP (Emollient) to other people. It may harm them.

This leaflet summarizes the most important information about Tretinoin Cream, USP (Emollient). If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about Tretinoin Cream, USP (Emollient) that is written for health professionals.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

SUNEVA MEDICAL INC.  
San Diego, CA 92121
TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine injected followed by 20 mL of a 50:50 mixture of liposomal bupivacaine and normal saline. This will then be repeated on the contralateral side. In the same arm the surgeon infiltration into the incision will consist of 10 ml of normal saline per port site, 5 ml prior to incision and 5 ml prior to closure at each port site.
PURPOSE:To obtain a safe cosmetic composition for beautifying and whitening having high effects. CONSTITUTION:The characteristic of this cosmetic composition for beautifying and whitening comprises an extract of at least one galenical of the group of GAIYO (Artemisiae Argyi Folium), SANSONIN (Zizyphi Spinosi Semen.), SHUROYO (a leaf of Trachycarpus wagnerianus), SEIMOKKO (a root of Vladimiria berardioides, Vladimiria forrestii and Vladimiria edulis), SOKYO (a fruit of Gleditsia sinensis Lam.), TAISO (Zizyphi Inermi Fructus), HAKUSENPI (the root bark of Dictamnus dasycarpus), BYAKUREN (a root of Ampelopsis japonica Makino), HAKUMOKUJI (a fruit body of Tremella fuciformis), MOKKA (Chaenomeles Fructus), IKURININ (Prunus Japonicae Semen), KYONIN (Armeniacae Semen), SEKINANYO (a dried leaf of Photinia serrulata Lindl.), HAKKYO (a stem and a leaf of Lactuca scariola), KAISHUNSHI (a branch, a leaf and a fruit of Cotoneaster acutifolius), IRYOSAI (a root or the whole herb with the root of Potentilla chinensis), DOBAIMO (a tuber of Bolbostemma paniculatum), HIREN (the whole herb or a root of Carduus crispus L.), CHOREI (Fungus Umbellatus), CHOMOSAI (the whole herb of Salsola collina), NYUHAKUKOSEI (the dried whole herb of Anaphalis lacteal, KYUSETSUSHOBU (Rhizoma Anemone), TAISEIKON (a root of Clerodendron cyrtophyllum) and KARENTOSAI (the whole herb of Drymaria cordata) as an active ingredient. This extract is capable of remarkably suppressing the melanogenesis without manifesting cytotoxocity. Thereby, the cosmetic composition for beautifying and whitening containing at least one of the extracts is safe and has high beautfying and whitening effects.
Impaired Liver Function 

Do not use ZAFEMY in women with liver disease, such as acute viral hepatitis or severe (decompensated) cirrhosis of liver [see Contraindications (4)]. Discontinue ZAFEMY if jaundice develops. Acute or chronic disturbances of liver function may necessitate the discontinuation of CHC use until markers of liver function return to normal and CHC causation has been excluded. 

Liver Tumors 

ZAFEMY is contraindicated in women with benign and malignant liver tumors [see Contraindications (4)]. Hepatic adenomas are associated with CHC use. An estimate of the attributable risk is 3.3 cases/100,000 CHC users. Rupture of hepatic adenomas may cause death through intra-abdominal hemorrhage. 

Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (>8 years) CHC users. However, the risk of liver cancers in CHC users is less than one case per million users.
The newly developed electrochemical device for H. pylori detection consists of a working and reference electrode between which a biopsy sample is administered. Afterwards, acquired voltage-values could be analysed for characteristics typical for H. pylori infection (ammonia). According to Sydney classification, biopsies are taken from gastric antrum and corpus for electrochemical H. pylori detection, HUT and immunohistochemistry (IHC). HUT results are evaluated after 24 hours. Furthermore, every patient will receive 13C-urea breath test. IHC is designated as the gold standard of H. pylori diagnosis.
The invention relates to a medicament used for clearing heat-toxin, cooling blood and dissipating blood stasis, in particular to a medicament of rhinoceros horn and rhizoma rehmanniae which is used for treating blood diseases. The invention provides the medicament of rhinoceros horn and rhizoma rehmanniae which can be used for treating blood diseases thoroughly with quick effect. The medicament consists of 1.5g to 3g of rhinoceros horn, 15g of rhizoma rehmanniae, 6g of Chinese herbaceous peony, 5g of peony, and a proper amount of oyster, plantago seed, cortex cinnamomi and radix scutellariae, as well as 15g of talcum and 15g of gypsum. The components of the medicament are decocted with 1800ml of water into a liquid medicament of 600ml. The dosage of the liquid medicament is 60ml each time. The adoption of the medicament can clear heat-toxin, cool the blood, dissipate blood stasis, remove dampness through diuresis and stanch bleeding and has obvious therapeutic effect in treating the bleeding symptoms caused by excessive heat, such as haematemesis, haematuria, hematochezia, blue and black spots, dark red tongue with burs generation and the like which belong to the symptom of heat attacking blood phase or haematuria caused by injury in antrum and diaphragm.
For VCAS-II group, patients with symptomatic frequent unifocal premature ventricular complexes (PVCs) meeting class II-a/b indications based on European guidelines for catheter ablation. For VCAS-II, documentation of frequent PVCs by 24 hours Holter with \>15% PVC burden for asymptomatic patients and \>5% PVC burden for symptomatic patients within the last 60 days.
1528419 Microcapsules TAKEDA YAKUHIN KOGYO KK 17 Aug 1976 [18 Aug 1975] 34193/76 Heading B8C A method of producing a micro-encapsulated product comprises (a) dissolving an oil-and-fat which is solid at room temperature in an organic solvent by heating, the organic solvent being incapable of dissolving a core material to be encapsulated but capable of dissolving the oil-andfat when hot and capable of co-acervating the oil and fat when cold; (b) dispersing the core material in the resulting solution; (c) cooling the dispersion with stirring to co-acervate the oil-and-fat on the core material; and (d) recovering and drying the encapsulated particulate product. The oil-and-fat is suitably a hydrogenated oil-and-fat, solid fat or a synthetic solid glyceride. The core material may be a feed additive, medicine, agricultural chemical or food additive. A polymer such as a cellulose derivative or an acrylic copolymer, may be dissolved with the oil-and-fat in the organic solvent as in step (a). The product of step (d) may be mixed with a powdery hydrophilic carrier, e.g. magnesium stearate, aluminium stearate or talc, heated and then cooled.
Participant will be randomized into the DSMT study arm for the first 6 months. At the 6-month rerandomization point, if the patient is a non-responder (A1c has not improved by at least 1 percentage point), patient will be randomized again with one arm being a CHW to provide tailored support.
The present invention relates to a chlorophyll ferrous microcapsule and a preparation method thereof and belongs to the technical field of medicines. The chlorophyll ferrous microcapsule overcomes the defects that the clinical effect of chlorophyll ferrous is poor and the drug loading capacity is limited due to the adoption of multiple core materials in the prior art. The core materials of the chlorophyll ferrous microcapsule are improved in prescription and a corresponding preparation method is provided. The chlorophyll ferrous microcapsule prepared based on the above method is high in drug loading capacity and encapsulation efficiency. The effect of the chlorophyll ferrous microcapsule is significantly superior to the individual application effect of chlorophyll ferrous in clinically treating anemia. Therefore, the chlorophyll ferrous microcapsule has a good application prospect.
An improved Vitamin K3 composition comprises a granular Vitamin K3 alkali metal bisulphite compound the grains of which are coated with a coating substance soluble or swellable in water and soluble in at least one volatile organic solvent, e.g. polyethylene glycols polyvinyl pyrrolidones and methyl and ethyl celluloses.  The preferred Vitamin K3 compound is the sodium bisulphite compound. Prior to granulation the Vitamin K3 compound may be mixed with one or more carbohydrates, e.g. lactose, glucose, maltose, saccharose sugar alcohols, e.g. mannitol, starch or starch product.  The mixture is granulated with starch glue, aqueous gelatin solution or an alcoholic solution of polyvinyl pyrrolidone.  Optional additions are (a) antioxidants such as sodium or potassium metabisulphite and ascorbic acid and (b) non-toxic sequestering agents such as ethylene diamine tetra-acetic acid.  The granules may be added to an animal feedstuff especially a poultry feedstuff to provide a stable product, or may be incorporated in pharmaceutical compositions such as tablets and capsules.
OBJECTIVE: This study aims to investigate the pathogenesis of hyperglycemia and its associated vasculopathy using multiomics analyses in diabetes and impaired glucose tolerance, and validate the mechanism using the cell experiments.
METHODS: In this study, we conducted a comprehensive analysis of the metagenomic sequencing data of diabetes to explore the key genera related to its occurrence. Subsequently, participants diagnosed with impaired glucose tolerance (IGT), and healthy subjects, were recruited for fecal and blood sample collection. The dysbiosis of the gut microbiota (GM) and its associated metabolites were analyzed using 16S rDNA sequencing and liquid chromatograph mass spectrometry, respectively. The regulation of gene and protein expression was evaluated through mRNA sequencing and data-independent acquisition technology, respectively. The specific mechanism by which GM dysbiosis affects hyperglycemia and its related vasculopathy was investigated using real-time qPCR, Western blotting, and enzyme-linked immunosorbent assay techniques in HepG2 cells and neutrophils.
RESULTS: Based on the published data, the key alterable genera in the GM associated with diabetes were identified as Blautia, Lactobacillus, Bacteroides, Prevotella, Faecalibacterium, Bifidobacterium, Ruminococcus, Clostridium, and Lachnoclostridium. The related metabolic pathways were identified as cholate degradation and L-histidine biosynthesis. Noteworthy, Blautia and Faecalibacterium displayed similar alterations in patients with IGT compared to those observed in patients with diabetes, and the GM metabolites, tauroursodeoxycholic acid (TUDCA) and carnosine (CARN, a downstream metabolite of histidine and alanine) were both found to be decreased, which in turn regulated the expression of proteins in plasma and mRNAs in neutrophils. Subsequent experiments focused on insulin-like growth factor-binding protein 3 and interleukin-6 due to their impact on blood glucose regulation and associated vascular inflammation. Both proteins were found to be suppressed by TUDCA and CARN in HepG2 cells and neutrophils.
CONCLUSION: Dysbiosis of the GM occurred throughout the entire progression from IGT to diabetes, characterized by an increase in Blautia and a decrease in Faecalibacterium, leading to reduced levels of TUDCA and CARN, which alleviated their inhibition on the expression of insulin-like growth factor-binding protein 3 and interleukin-6, contributing to the development of hyperglycemia and associated vasculopathy.
BACKGROUND: Sepsis is a severe complication that results in increased morbidity and mortality after intestinal obstruction surgery. This study examined the role of preoperative systemic immune inflammation index (SII) for postoperative sepsis in intestinal obstruction patients.
METHODS: Data on patients who underwent intestinal obstruction surgery were collected. SII was determined and separated into two groups (≤1792.19 and >1792.19) according to the optimal cut-off value of SII for postoperative sepsis. The odds ratio (OR) is calculated for the correlation between SII and postoperative sepsis. Additional analyses were used to estimate the robustness of SII.
RESULTS: A total of 371 intestinal obstruction patients undergoing surgery were included in the final cohort, and 60 (16.17%) patients developed postoperative sepsis. Patients with an SII >1792.19 had a significantly higher risk for developing postoperative sepsis after multivariable adjustment [adjusted odds ratio = 2.12, 95% confidence interval: [1.02-4.40]]. The analysis of interaction showed no correlation between the preoperative SII and postoperative sepsis regarding age, hypertension, American Society of Anesthesiologists classification, blood loss, albumin, hemoglobin, creatinine, and leukocyte (all interactions p > .05). In subgroup analysis, all statistically significant subgroups showed that SII was a risk factor for postoperative sepsis (all p < .05). The analyses of subgroups and interactions revealed that the interaction effect of a preoperative SII >1792.19 and postoperative sepsis remained significant. A sensitivity analysis confirmed the robustness of the results.
CONCLUSIONS: A preoperative SII > 1792.19 was a risk factor for postoperative sepsis in patients undergoing intestinal obstruction surgery.
Differentiation and stability of neural stem cells can be enhanced by in vitro or in vivo culturing with one or more extracellular matrix (ECM) compositions, such as collagen I, IV, laminin and/or a heparan sulfate proteoglycan. In one aspect of the invention, adult mammalian enteric neuronal progenitor cells can be induced to differentiate on various substrates derived from components or combinations of neural ECM compositions. Collagen I and IV supported neuronal differentiation and extensive glial differentiation individually and in combination. Addition of laminin or heparan sulfate to collagen substrates unexpectedly improved neuronal differentiation, increasing neuron number, branching of neuronal processes, and initiation of neuronal network formation. In another aspect, neuronal subtype differentiation was affected by varying ECM compositions in hydrogels overlaid on intestinal smooth muscle sheets. The matrix compositions of the present invention can be used to tissue engineer transplantable innervated GI smooth muscle constructs to remedy aganglionic disorders.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to heparins of the low-molecular mass obtained by nitrose depolymerization of the natural heparin and containing nitros compounds at amount less or equal to 5 x 10 -7  mg/mg product. For removal of nitros compounds an aqueous solution of low-molecular mass heparin is treated by ultraviolet rays (wavelength is from 180 to 350 nm) at temperature 5-50 C and pH 3-8. For preparing the purified low-molecular mass heparin an aqueous solution of the natural heparin sodium salt (concentration is 5-15 wt. -%/vol. ) is treated with alkaline metal nitrite as measured 1.5-6.9 wt.-% nitrite to heparin salt taken. The indicated reaction is carried out in the presence of hydrochloric acid at pH from 1 to 5 for time from 20 to 50 min up to negative test for nitro-ions. Obtained product is reduced by addition of sodium boron hydride at amount 0.5-2.0 wt. -% of heparin salt amount taken. An excess of boron hydride is decomposed with hydrochloric acid. Obtained reaction medium is neutralized and the low-molecular mass heparin is precipitated with ethanol as a sodium salt. An aqueous solution of the obtained sodium salt is treated by ultraviolet rays. For preparing nitros compound-containing product at amount less or equal to 5 x 10 -8  mg/mg product the solution treated by ultraviolet rays is fed additionally on anion-exchange column. The indicated column is washed out with water at pH about 7 and the end product is recuperated by precipitation with sodium chloride and ethanol. Pharmaceutical composition based on the low-molecular mass purified heparin shows antithrombosis activity. Method of purification of the low-molecular mass heparin from nitros compounds by ultraviolet irradiation ensures to retain its biological and physical-chemical properties. EFFECT: improved method of preparing. 17 cl, 2 tbl, 2 dwg, 2 ex